These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23735279)

  • 1. Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates.
    Choi YS; Hou S; Choe LH; Lee KH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jul; 930():129-35. PubMed ID: 23735279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease.
    Choi YS; Lee KH
    Arch Pharm Res; 2016 Mar; 39(3):390-7. PubMed ID: 26404792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
    Paterson RW; Heywood WE; Heslegrave AJ; Magdalinou NK; Andreasson U; Sirka E; Bliss E; Slattery CF; Toombs J; Svensson J; Johansson P; Fox NC; Zetterberg H; Mills K; Schott JM
    Transl Psychiatry; 2016 Nov; 6(11):e952. PubMed ID: 27845782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.
    Liu Y; Qing H; Deng Y
    Int J Mol Sci; 2014 May; 15(5):7865-82. PubMed ID: 24806343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
    Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J
    J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
    Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
    Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
    Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
    Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.
    Perrin RJ; Payton JE; Malone JP; Gilmore P; Davis AE; Xiong C; Fagan AM; Townsend RR; Holtzman DM
    PLoS One; 2013; 8(5):e64314. PubMed ID: 23700471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform.
    Oh JH; Pan S; Zhang J; Gao J
    Rapid Commun Mass Spectrom; 2010 Feb; 24(4):403-8. PubMed ID: 20069694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteome studies of CSF in AD patients.
    Davidsson P; Sjögren M
    Mech Ageing Dev; 2006 Feb; 127(2):133-7. PubMed ID: 16293296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.
    Roher AE; Maarouf CL; Sue LI; Hu Y; Wilson J; Beach TG
    Biomarkers; 2009 Nov; 14(7):493-501. PubMed ID: 19863188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
    Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
    Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
    Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
    J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome.
    Shayan G; Adamiak B; Choe LH; Relkin N; Lee KH
    Electrophoresis; 2014 Jul; 35(12-13):1821-7. PubMed ID: 24756957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review.
    Wesenhagen KEJ; Teunissen CE; Visser PJ; Tijms BM
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):86-98. PubMed ID: 31694431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.